Ownership and insider activity for Abivax S.A. (ABVX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19.
Price
| Price | $105.04 |
| Market Cap | $7.7B |
| Exchange | NASDAQ |
| Country | FR |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.9M | $1.9M | $8.0M | $9.8M | $29.3M | $60.7M | $26.9M | $251.9M | $144.2M | $516.5M |
| Short-term Investments | $15.1M | $15.2M | $5.0M | $6000 | $6000 | $6000 | 0 | $9.1M | 0 | $13.7M |
| Receivables | $4.8M | $3.6M | $7.8M | $7.0M | $8.0M | $8.3M | $8.3M | $19.1M | $15.7M | $10.5M |
| Inventory | $52000 | $199000 | 0 | $1.2M | 0 | $4.0M | 0 | 0 | 0 | 0 |
| Total Current Assets | $27.8M | $20.9M | $21.0M | $18.2M | $37.7M | $75.2M | $36.2M | $286.0M | $170.7M | $551.0M |
| Property, Plant & Equipment | $192000 | $201000 | $151000 | $134000 | $100000 | $93000 | $1.6M | $877000 | $2.7M | $2.1M |
| Goodwill | $32.0M | $32.0M | $32.0M | $32.0M | $32.0M | $32.7M | $18.4M | $18.4M | $18.4M | $18.4M |
| Intangible Assets | 0 | 0 | 0 | $85000 | $98000 | -$647000 | $6.6M | $6.6M | $6.6M | $6.6M |
| Total Assets | $60.6M | $53.8M | $54.0M | $51.7M | $71.3M | $109.2M | $75.5M | $327.1M | $205.2M | $584.1M |
| Accounts Payable | $2.6M | $4.2M | $6.7M | $10.5M | $17.4M | $18.6M | $15.5M | $47.2M | $43.8M | $37.6M |
| Short-term Debt | $255000 | 0 | $10.9M | $20.7M | $12000 | $10.1M | $29.5M | $30.9M | $42.8M | $28.5M |
| Total Current Liabilities | $3.5M | $5.4M | $8.5M | $12.4M | $19.4M | $32.3M | $51.5M | $88.1M | $92.8M | $63.0M |
| Long-term Debt | $316000 | 0 | $10.9M | $20.7M | $34.0M | $40.3M | $8.3M | $26.6M | $52.2M | $30.2M |
| Total Liabilities | $3.9M | $5.6M | $19.4M | $33.1M | $53.4M | $83.3M | $68.4M | $131.1M | $164.6M | $129.1M |
| Retained Earnings | -$35.4M | -$46.6M | -$62.4M | -$93.0M | -$37.6M | -$81.8M | -$143.5M | -$282.9M | -$438.9M | -$738.2M |
| Total Equity | $56.7M | $48.2M | $34.7M | $18.6M | $17.9M | $25.9M | $7.2M | $196.0M | $40.6M | $455.0M |
| Total Debt | $316000 | 0 | $10.9M | $20.7M | $34.0M | $51.7M | $39.2M | $58.0M | $97.4M | $45.9M |
| Net Debt | -$22.7M | -$17.0M | -$2.1M | $11.0M | $4.7M | -$9.0M | $12.2M | -$202.9M | -$46.9M | -$484.3M |
| Working Capital | $24.3M | $15.4M | $12.5M | $5.9M | $18.3M | $42.9M | -$15.3M | $197.9M | $77.8M | $488.0M |
Financial Health
| Debt / Equity | 0.10 |
| Current Ratio | 8.75 |
Profitability
| Return on Equity | -165.19% |
| Return on Invested Capital | -45.51% |
| Return on Assets | -57.52% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AXSM · CORT · CYTK · HALO · JAZZ · MDGL · MRUS
Explore sector: Healthcare · Biotechnology
More sections of ABVX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks